Long-Term Effects of High-Dose Tolvaptan for Autosomal Dominant Polycystic Kidney Disease Patients

Long-Term Effects of High-Dose Tolvaptan for Autosomal Dominant Polycystic Kidney Disease Patients

Tolvaptan, a vasopressin V2 receptor antagonist, was initially approved in Japan for treatment of autosomal dominant polycystic kidney disease (ADPKD). Recently, a retrospective study showed that the effect of tolvaptan on kidney function could be sustained for a long period. However, the long-term...

Full description

Bibliographic Details
Main Authors: Shinya Nakatani, Eiji Ishimura, Yuri Machiba, Kenta Fujimoto, Hideki Uedono, Akihiro Tsuda, Katsuhito Mori, Masanori Emoto, Masaaki Inaba
Format: Article
Language:English
Published: Karger Publishers 2020-02-01
Series:Case Reports in Nephrology and Dialysis
Subjects:
autosomal dominant polycystic kidney disease
tolvaptan
high dose
long term
Online Access:https://www.karger.com/Article/FullText/506118

Internet

https://www.karger.com/Article/FullText/506118

Similar Items